News blog

Cancer vaccine approved

A controversial prostate cancer vaccine has become the first therapeutic cancer vaccine to receive regulatory approval in the United States.

On 29 April, the US Food and Drug Administration (FDA) approved Provenge (sipuleucel-T) for the treatment of advanced hormone-resistant prostate cancer. Stock in , the vaccine’s Seattle, Washington-based manufacturer, rose 27% on the announcement.

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE